These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 7669712

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I.
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [Abstract] [Full Text] [Related]

  • 8. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
    Scheithauer W, Cortelezzi A, Fritz E, Kührer I, Polli E, Baldini L, Ludwig H.
    J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740
    [Abstract] [Full Text] [Related]

  • 9. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Bladé J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, Arias J, García-Conde J, Carnero M, Marti JM, Rozman C, Estapé J, Montserrat E.
    Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel R J, O'Connell M J.
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
    Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W.
    J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
    [Abstract] [Full Text] [Related]

  • 14. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 15. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
    Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BG, Kuzmits R, Fillet G, Peetermans M, Polli E, Flener R.
    Eur J Cancer Clin Oncol; 1986 Sep 15; 22(9):1111-6. PubMed ID: 3536528
    [Abstract] [Full Text] [Related]

  • 16. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tarkovács G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A.
    Br J Haematol; 2005 Nov 15; 131(3):329-37. PubMed ID: 16225652
    [Abstract] [Full Text] [Related]

  • 17. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
    Preis P, Scheithauer W, Fritz E, Zielinski C, Kuehrer I, Cortelezzi A, Polli E, Baldini L, Pirker R, Kriegisch A.
    Onkologie; 1989 Feb 15; 12(1):27-9. PubMed ID: 2654788
    [Abstract] [Full Text] [Related]

  • 18. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan 15; 124(2):212-22. PubMed ID: 8533996
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Peest D, Deicher H, Coldewey R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, Göbel B.
    Eur J Cancer; 1995 Jan 15; 31A(2):146-51. PubMed ID: 7718318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.